Yvan Vandenplas1, Elisabeth De Greef2, I Xinias3, O Vrani3, A Mavroudi3, M Hammoud4, F Al Refai4, M C Khalife5, A Sayad5, P Noun5, A Farah5, G Makhoul6, R Orel7, M Sokhn8, A L'Homme9, M P Mohring9, B Abou Merhi10, J Boulos11, H El Masri12, C Halut13. 1. UZ Brussel, Department of Pediatrics, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: yvan.vandenplas@uzbrussel.be. 2. UZ Brussel, Department of Pediatrics, Vrije Universiteit Brussel, Brussels, Belgium. 3. Department of Pediatrics, Hippocration Hospital, Thessaloniki, Greece. 4. Faculty of Medicine, Department of Pediatrics, Kuwait University, Kuwait City, Kuwait. 5. Holy Spirit University of Kaslik, Kaslikand UH-NDS, Beyruth, Lebanon. 6. Tripoli, Lebanon. 7. University Children's Hospital, Ljubljana, Slovenia. 8. University of Balamand, Beirut, Lebanon. 9. Department of Pediatrics, La Citadelle Regional Hospital, Liège, Belgium. 10. Beirut, Lebanon. 11. Mount Lebanon Hospital, Beyruth, Lebanon. 12. Bahman Hospital, Medical Director Dar Hawraa Center, Beyruth, Lebanon. 13. Department of Pediatrics, Regional Hospital, Namur, Belgium.
Abstract
OBJECTIVES:Cow's milk allergy (CMA) is treated in formula-fed infants with an extensive protein hydrolysate. This study aimed to evaluate the nutritional safety of a non-thickened and thickened extensively casein hydrolyzed protein formula (NT- and T-eCHF) in infants with CMA. METHODS:Infants younger than 6 mo old with a positive cow milk challenge test, positive IgE, or skin prick test for cow milk were selected. Weight and length were followed during the 6 mo intervention with the NT-eCHF and T-eCHF. RESULTS: A challenge was performed in 50/71 infants with suspected CMA and was positive in 34/50. All children with confirmed CMA tolerated the eCHF. The T-eCHF leads to a significant improvement of the stool consistency in the whole population and in the subpopulation of infants with proven CMA. Height and weight evolution was satisfactory throughout the 6 mo study. CONCLUSIONS: The eCHF fulfills the criteria of a hypoallergenic formula and the NT- and T-eCHF reduced CMA symptoms. Growth was within normal range.
RCT Entities:
OBJECTIVES:Cow's milk allergy (CMA) is treated in formula-fed infants with an extensive protein hydrolysate. This study aimed to evaluate the nutritional safety of a non-thickened and thickened extensively casein hydrolyzed protein formula (NT- and T-eCHF) in infants with CMA. METHODS:Infants younger than 6 mo old with a positive cow milk challenge test, positive IgE, or skin prick test for cow milk were selected. Weight and length were followed during the 6 mo intervention with the NT-eCHF and T-eCHF. RESULTS: A challenge was performed in 50/71 infants with suspected CMA and was positive in 34/50. All children with confirmed CMA tolerated the eCHF. The T-eCHF leads to a significant improvement of the stool consistency in the whole population and in the subpopulation of infants with proven CMA. Height and weight evolution was satisfactory throughout the 6 mo study. CONCLUSIONS: The eCHF fulfills the criteria of a hypoallergenic formula and the NT- and T-eCHF reduced CMA symptoms. Growth was within normal range.